2099 Stock Overview
Operates as a pharmaceutical company in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Zhejiang Hisoar Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.20 |
| 52 Week High | CN¥10.11 |
| 52 Week Low | CN¥3.91 |
| Beta | 0.48 |
| 11 Month Change | -11.86% |
| 3 Month Change | -6.14% |
| 1 Year Change | -40.64% |
| 33 Year Change | -32.64% |
| 5 Year Change | -35.80% |
| Change since IPO | -42.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2099 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -8.3% | -5.0% | -3.6% |
| 1Y | -40.6% | -13.7% | -16.0% |
Return vs Industry: 002099 underperformed the CN Pharmaceuticals industry which returned -13.7% over the past year.
Return vs Market: 002099 underperformed the CN Market which returned -16% over the past year.
Price Volatility
| 2099 volatility | |
|---|---|
| 2099 Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in CN Market | 10.2% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 002099's share price has been volatile over the past 3 months.
Volatility Over Time: 002099's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 2,612 | Guorui Xu | www.hisoar.com |
Zhejiang Hisoar Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally. The company offers antibiotics, cardiovascular products, hypoglycemic products, fine chemicals, dyes, intermediates, and other products, as well as clindamycin products. It also provides pharmaceutical, dyestuff, and other related services.
Zhejiang Hisoar Pharmaceutical Co., Ltd. Fundamentals Summary
| 2099 fundamental statistics | |
|---|---|
| Market cap | CN¥8.30b |
| Earnings (TTM) | -CN¥429.56m |
| Revenue (TTM) | CN¥2.07b |
4.0x
P/S Ratio-19.5x
P/E RatioIs 2099 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2099 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.07b |
| Cost of Revenue | CN¥1.84b |
| Gross Profit | CN¥228.58m |
| Other Expenses | CN¥658.14m |
| Earnings | -CN¥429.56m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 11.06% |
| Net Profit Margin | -20.79% |
| Debt/Equity Ratio | 24.0% |
How did 2099 perform over the long term?
See historical performance and comparison